Table 3.
Trend in the anti-tuberculosis drug resistance rate of Mycobacterium tuberculosis isolates from previously treated cases
| Variable | Year |
Total | p for trend | ||||
|---|---|---|---|---|---|---|---|
| 2010 | 2011 | 2012 | 2013 | 2014 | |||
| No. of cases | 126 | 152 | 131 | 138 | 125 | 672 | |
| Isoniazid | 48 (38.1) | 54 (35.5) | 51 (38.9) | 47 (34.1) | 38 (30.4) | 238 (35.4) | 0.223 |
| Rifampin | 37 (29.4) | 47 (30.9) | 26 (19.8) | 35 (25.4) | 24 (19.2) | 169 (25.1) | 0.032 |
| Rifabutin | 23 (18.3) | 35 (23.0) | 20 (15.3) | 27 (19.6) | 19 (15.2) | 124 (18.5) | 0.352 |
| Ethambutol | 24 (19.0) | 25 (16.4) | 14 (10.7) | 23 (16.7) | 19 (15.2) | 105 (15.6) | 0.491 |
| Pyrazinamide | 15 (11.9) | 15 (9.9) | 8 (6.1) | 23 (16.7) | 10 (8.0) | 71 (10.6) | 1.000 |
| Streptomycin | 12 (9.5) | 11 (7.2) | 13 (9.9) | 12 (8.7) | 11 (8.8) | 59 (8.8) | 1.000 |
| Kanamycin | 11 (8.7) | 9 (5.9) | 1 (0.8) | 11 (8.0) | 2 (1.6) | 34 (5.1) | 0.057 |
| Capreomycin | 11 (8.7) | 4 (2.6) | 1 (0.8) | 9 (6.5) | 1 (0.8) | 26 (3.9) | 0.043 |
| Amikacin | 11 (8.7) | 3 (2.0) | 1 (0.8) | 9 (6.5) | 2 (1.6) | 26 (3.9) | 0.113 |
| Ofloxacin | 15 (11.9) | 16 (10.5) | 8 (6.1) | 17 (12.3) | 7 (5.6) | 63 (9.4) | 0.216 |
| Levofloxacin | 14 (11.1) | 13 (8.6) | 8 (6.1) | 15 (10.9) | 7 (5.6) | 57 (8.5) | 0.296 |
| Moxifloxacin | 12 (9.5) | 12 (7.9) | 5 (3.8) | 13 (9.4) | 7 (5.6) | 49 (7.3) | 0.424 |
| Prothionamide | 10 (7.9) | 12 (7.9) | 4 (3.1) | 11 (8.0) | 4 (3.2) | 41 (6.1) | 0.165 |
| Cycloserin | 7 (5.6) | 6 (3.9) | 1 (0.8) | 2 (1.4) | 1 (0.8) | 17 (2.5) | 0.005 |
| Para-aminosalicylic acid | 12 (9.5) | 20 (13.2) | 9 (6.9) | 13 (9.4) | 4 (3.2) | 58 (8.6) | 0.033 |
| Any drug | 50 (8.7) | 56 (36.8) | 54 (41.2) | 51 (37.0) | 42 (33.6) | 253 (37.6) | 0.406 |
| MDR | 36 (28.6) | 45 (29.6) | 25 (19.1) | 33 (23.9) | 23 (18.4) | 162 (24.1) | 0.027 |
| Pre-XDR | 6 (4.8) | 15 (9.9) | 7 (5.3) | 8 (5.8) | 5 (4.0) | 41 (6.1) | 0.355 |
| XDR | 10 (7.9) | 6 (3.9) | 0 (0.0) | 9 (6.5) | 2 (1.6) | 27 (4.0) | 0.089 |
Values are presented as number (%).
MDR, multidrug resistance; XDR, extensively drug resistance.